» Articles » PMID: 19307800

Requirement of Protocol Biopsy Before and After Complete Cessation of Immunosuppression After Liver Transplantation

Abstract

Background: Operational tolerance is defined as long-term acceptance of a transplanted organ after complete cessation of immunosuppression (IS), but may not always protect against antigen-dependent changes in graft morphology.

Method: IS free patients after living-donor liver transplantation (LDLT) underwent protocol biopsy (tolerance group [Gr-Tol]) and were evaluated for rejection and fibrosis. The degree of fibrosis was compared with those in the patients on maintenance IS group (Gr-IS) and the base line normal liver group (Gr-BS). When bridging fibrosis or progression of fibrosis was observed, IS was reintroduced or increased in Gr-Tol or in the patients in the weaning process.

Results: Neither acute nor chronic rejection was observed. The degree of fibrosis, however, was significantly greater in Gr-Tol than those in Gr-IS and Gr-BS. In Gr-Tol, the number of graft infiltrating FOXP3 cells was significantly increased, the interval between LDLT and biopsy plus the donor age was significantly longer, and recipient age at LDLT was significantly younger, compared with those in Gr-IS. However, none of these three parameters correlated with the degree of fibrosis. In 7 of 11 patients in whom IS was reintroduced or increased, the improvement of fibrosis was observed by the subsequent biopsy.

Conclusion: Grafts of operationally tolerant patients after LDLT did not exhibit acute or chronic rejection, but they exhibited fibrosis. It remains elusive whether fibrosis observed in tolerant grafts is antigen dependent. The finding that after [corrected] the reintroduction or the increase of IS fibrosis was improved supported the possibility that fibrosis in operationally tolerant patients was antigen dependent.

Citing Articles

Donor-Specific Antibodies Against Donor Human Leukocyte Antigen are Associated with Graft Inflammation but Not with Fibrosis Long-Term After Liver Transplantation: An Analysis of Protocol Biopsies.

Gul-Klein S, Hegermann H, Rohle R, Schmelzle M, Tacke F, Schoning W J Inflamm Res. 2021; 14:2697-2712.

PMID: 34188517 PMC: 8236257. DOI: 10.2147/JIR.S307778.


Strategies for Liver Transplantation Tolerance.

Cvetkovski F, Hexham J, Berglund E Int J Mol Sci. 2021; 22(5).

PMID: 33668238 PMC: 7956766. DOI: 10.3390/ijms22052253.


Strategies for immune regulation in iPS cell-based cardiac regenerative medicine.

Murata K, Ikegawa M, Minatoya K, Masumoto H Inflamm Regen. 2020; 40:36.

PMID: 33005258 PMC: 7523082. DOI: 10.1186/s41232-020-00145-4.


Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

Du X, Chang S, Guo W, Zhang S, Chen Z Front Immunol. 2020; 11:1326.

PMID: 32670292 PMC: 7326808. DOI: 10.3389/fimmu.2020.01326.


malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature.

Manzia T, Angelico R, Gazia C, Lenci I, Milana M, Ademoyero O World J Gastroenterol. 2019; 25(35):5356-5375.

PMID: 31558879 PMC: 6761240. DOI: 10.3748/wjg.v25.i35.5356.